A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Exemestane (Primary) ; Letrozole (Primary)
- Indications Carcinoma; Early breast cancer
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Acronyms ELPh
- 07 Jun 2022 Results (n=131) assessing the relationship between use of prescription and over-the-counter (OTC) medications and AI discontinuation in older women, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Results (n=228) identifying, genetic variants that affect steady state letrozole concentrations in patients with breast cancer, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 01 Jul 2017 According to results published in the Breast Cancer Research and Treatment Journal, after 132 patients had been enrolled, an amendment to the protocol allowed patients with self-reported intolerance to the aromatase inhibitor (AI) to which they were originally randomized to crossover to the other study-provided AI.